ST Pharm and Quantoom Biosciences have announced an extended collaboration to advance the development and manufacturing of RNA-based vaccines and therapeutics. This partnership integrates the complementary strengths of both companies to enhance the global supply of critical RNA manufacturing technologies.
Evonik is partnering with KNAUER Wissenschaftliche Geräte GmbH to enhance the scale-up process for lipid nanoparticle (LNP) formulations. The collaboration aims to improve efficiency and speed up the transition from small-scale prototypes to production-scale formulations, reducing preclinical development time. The
Phosphorex, a contract development and manufacturing organization (CDMO) specializing in drug delivery, announced today that NOF CORPORATION has completed a strategic investment in the company. This investment, backed by Ampersand Capital Partners, marks a crucial step in Phosphorex’s expansion efforts.
Agilent Technologies Inc. has announced a definitive agreement to acquire BIOVECTRA, a specialized contract development and manufacturing organization (CDMO), for $925 million. The acquisition aims to enhance Agilent’s capabilities in biologics, highly potent active pharmaceutical ingredients, and other targeted therapeutics. BIOVECTRA, based
CordenPharma, a global CDMO specialising in the manufacture of Drug Substances (APIs) for complex modalities, and Certest, a Spanish company focused on developing new products in Drug Delivery, have announced a partnership agreement. The collaboration is set to add ionizable
Aldevron, a global manufacturer of DNA, RNA, and proteins, has announced a strategic partnership with Acuitas Therapeutics, a private biotechnology company that specialises in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs). The collaboration
The emerging field of mRNA therapeutics is still young. This class of therapeutics is poised to have broad implications in the treatment of many indications in addition to infectious diseases such as cancer, autoimmune diseases, and cardiovascular diseases, as well
FUJIFILM Toyama Chemical Co., Ltd and Synplogen Co., Ltd., a biotech startup company from Kobe University, have announced a strategic business alliance on Contract Development and Manufacturing Organisation (CDMO) services for mRNA therapeutics. FUJIFILM Toyama Chemical has been providing one-stop-shop CDMO
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
